Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Systemic inflammatory response and nutritional biomarkers as predictors of nivolumab efficacy for gastric cancer.

Tytuł:
Systemic inflammatory response and nutritional biomarkers as predictors of nivolumab efficacy for gastric cancer.
Autorzy:
Namikawa T; Department of Surgery, Kochi Medical School, Kohasu, Oko-cho, Nankoku, Kochi, 783-8505, Japan. .
Yokota K; Department of Surgery, Kochi Medical School, Kohasu, Oko-cho, Nankoku, Kochi, 783-8505, Japan.
Tanioka N; Department of Surgery, Kochi Medical School, Kohasu, Oko-cho, Nankoku, Kochi, 783-8505, Japan.
Fukudome I; Department of Surgery, Kochi Medical School, Kohasu, Oko-cho, Nankoku, Kochi, 783-8505, Japan.
Iwabu J; Department of Surgery, Kochi Medical School, Kohasu, Oko-cho, Nankoku, Kochi, 783-8505, Japan.
Munekage M; Department of Surgery, Kochi Medical School, Kohasu, Oko-cho, Nankoku, Kochi, 783-8505, Japan.
Uemura S; Department of Surgery, Kochi Medical School, Kohasu, Oko-cho, Nankoku, Kochi, 783-8505, Japan.
Maeda H; Department of Surgery, Kochi Medical School, Kohasu, Oko-cho, Nankoku, Kochi, 783-8505, Japan.
Kitagawa H; Department of Surgery, Kochi Medical School, Kohasu, Oko-cho, Nankoku, Kochi, 783-8505, Japan.
Kobayashi M; Department of Human Health and Medical Sciences, Kochi Medical School, Kochi, Japan.
Hanazaki K; Department of Surgery, Kochi Medical School, Kohasu, Oko-cho, Nankoku, Kochi, 783-8505, Japan.
Źródło:
Surgery today [Surg Today] 2020 Nov; Vol. 50 (11), pp. 1486-1495. Date of Electronic Publication: 2020 Jun 15.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: Tokyo : Springer International, c1992-
MeSH Terms:
Nutrition Assessment*
Antineoplastic Agents, Immunological/*therapeutic use
Nivolumab/*therapeutic use
Stomach Neoplasms/*drug therapy
Systemic Inflammatory Response Syndrome/*chemically induced
Aged ; Aged, 80 and over ; Antineoplastic Agents, Immunological/adverse effects ; Female ; Humans ; Leukocyte Count ; Lymphocytes/immunology ; Male ; Middle Aged ; Neutrophils/immunology ; Nivolumab/adverse effects ; Predictive Value of Tests ; Severity of Illness Index ; Stomach Neoplasms/immunology ; Treatment Outcome
Contributed Indexing:
Keywords: Gastric cancer; Immune checkpoint inhibitor; Immune-related adverse events; Neutrophil to lymphocyte ratio; Prognostic nutrition index; Programmed death-1
Substance Nomenclature:
0 (Antineoplastic Agents, Immunological)
31YO63LBSN (Nivolumab)
Entry Date(s):
Date Created: 20200617 Date Completed: 20201123 Latest Revision: 20201123
Update Code:
20240105
DOI:
10.1007/s00595-020-02048-w
PMID:
32542414
Czasopismo naukowe
Purpose: To investigate the usefulness of clinicopathological systemic inflammatory response and nutritional biomarkers for predicting the efficacy of nivolumab in patients with advanced gastric cancer.
Methods: The subjects of this study were 29 patients who received nivolumab treatment for advanced gastric cancer at the Kochi Medical School between 2017 and 2019. Clinicopathological information, including systemic inflammatory response data, were obtained to investigate the associations between baseline cancer-related prognostic variables and survival outcomes.
Results: Immune-related adverse events (irAEs) of any grade were identified in 34.5% (10/29) of the patients. The median progression-free survival of patients with irAEs was significantly greater than that of patients without irAEs (5.8 months vs. 1.2 months, respectively; P = 0.028). The neutrophil to lymphocyte ratio (NLR) after 4 weeks of treatment in the complete response (CR) or partial response (PR) group was significantly lower than that in the stable disease (SD) or progression disease (PD) group (2.2 vs. 2.9, respectively; P = 0.044). The prognostic nutrition index (PNI) before treatment in the CR or PR group was significantly higher than that in the SD or PD group (37.1 vs. 32.1, respectively; P = 0.011). The PNI 8 weeks after treatment and the Glasgow prognostic score (GPS) before treatment were significantly associated with a poor outcome.
Conclusion: The irAE, NLR, PNI, and GPS may be useful predictive markers for nivolumab efficacy in patients with advanced gastric cancer.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies